Human epidermal growth factor receptor 3-targeted near-infrared photoimmunotherapy in a xenograft mouse model of breast cancer
Makoto Kano, Aki Furusawa, Hiroshi Fukushima, Seiichiro Takao, Shuhei Okuyama, Hiroshi Yamamoto, Motofumi Suzuki, Ko Kitamura, Miyu Kano, Peter L Choyke, Hisataka Kobayashi · 2026
Read Human epidermal growth factor receptor 3-targeted near-infrared photoimmunotherapy in a xenograft mouse model of breast cancer by Makoto Kano, Aki Furusawa, Hiroshi Fukushima, Seiichiro Takao, Shuhei Okuyama, Hiroshi Yamamoto, Motofumi Suzuki, Ko Kitamura, Miyu Kano, Peter L Choyke, Hisataka Kobayashi (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13349167.txt.
Description
Makoto Kano and co-authors test a light-based therapy aimed at a growth receptor on breast cancer cells, in a mouse study from two thousand twenty-six. The receptor is HER3, found on most breast cancer types and linked to drug failure. The therapy joins an antibody to a dye that kills only lit cells bound by the antibody.
In dishes the treatment killed both a hard-to-treat cell type and a hormone-linked type. In mice with grafted tumors it slowed growth and lengthened survival. Three in ten mice with the hard type had full clearing of the tumor. No drug of this kind aimed at HER3 is yet approved for patients. Readers see strong early proof that still needs human trials.
Catalog record
| CREATOR | Makoto Kano, Aki Furusawa, Hiroshi Fukushima, Seiichiro Takao, Shuhei Okuyama, Hiroshi Yamamoto, Motofumi Suzuki, Ko Kitamura, Miyu Kano, Peter L Choyke, Hisataka Kobayashi |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 42 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |